Multiprofile Hospital For Active Treatment Hadji Dimitar OOD
- Address
- lock Available on a paid plan
Digestive System Diseases
The gastroenterology department at Multiprofile Hospital For Active Treatment Hadji Dimitar OOD is conducting research on Crohn's disease and hepatic encephalopathy, aiming to test new therapeutic options that can reduce disease activity and prevent hospital admissions.
- Rifaximin formulation to delay encephalopathy decompensation
- Subcutaneous RO7790121 for moderate to severe Crohn's disease
These studies highlight the hospital’s dedication to improving outcomes for patients with digestive disorders in Sliven, Bulgaria.
Eye Diseases
In the ophthalmology scope, the site evaluates treatments for open-angle glaucoma and ocular hypertension, focusing on sustained‑release therapies that maintain intra‑ocular pressure control when standard eye drops are insufficient.
- Bimatoprost SR to extend IOP‑lowering effect
- Assessment of alternative delivery methods for glaucoma management
The research reflects a commitment to advancing vision‑preserving options for patients across the region.
Musculoskeletal Diseases
The department also addresses post‑menopausal osteoporosis, conducting comparative studies to determine whether new biologics can match the efficacy of established treatments in improving bone health.
- BP16 equivalence study with EU‑Prolia on bone mineral density
- Evaluation of serum bone turnover markers for therapeutic monitoring
This work underscores the hospital’s role in fostering innovative solutions for bone‑related conditions in the community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1AstraZeneca AB3active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment Hadji Dimitar OOD
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized Study of IMVT-1402 Versus Placebo in Adult Patients with Graves' Disease | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 3 | Unknown | 2021-04-29 | 2024-07-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.